Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue grows, but more slowly than its trailing trend

Q2 FY2026 cost of revenue of $40.01M rose 341.3% year over year, behind the +470.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 49.0% from the prior quarter.

Context

  • Cost of revenue amounted to 5.9% of revenue in FY2025, up 2.4 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +341.3% toward the trailing-twelve-month pace of +470.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$40.01M+49.0% QoQ
Last fiscal yearDec 2025
$56.15M+800.8% YoY
LTMJun 2026
$109.42M+470.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+341.3%——
1 year+800.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
56.15M USD
Year-over-year change
+800.8%

Cost of Revenue vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +470.7% is the highest of 2, against a peer median of -28.0%.
  • Cost of revenue amounts to 8.5% of revenue for MDGL, versus a peer median of 35.2%.
MDGL Competitors
Cost of Revenue for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$109.42M USD+470.7%—8.5%
ALTAltimmune, Inc.LTM Mar 2026$14.98M USD——41619.4%
IVAInventiva S.A.FY2025€2.8M EUR-28.0%+41.1%62.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.59M USD——8.0%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$559K USD——7.9%
VKTXViking Therapeutics, Inc.LTM Jun 2026$208K USD———
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 USD———
Peer median (excluding MDGL) —-28.0%+41.1%35.2%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.